Category: Markets
Published: 2026-06-22T16:57:00.000Z
Erasca, Inc. faces a securities fraud class action lawsuit after disclosing a patent infringement allegation from Revolution Medicines on April 27, 2026, followed by a patient death in its ERAS-0015 Phase 1 trial on April 28, 2026. The stock plummeted 48.3% on April 28 after the death disclosure. The lawsuit alleges the company made materially false statements about ERAS-0015's preclinical data and failed to disclose material risks. The deadline to file a lead plaintiff motion is August 10, 2026.
News summary curated and translated by CausifyMarket. Always consult original sources before making any financial decision.